{"Ticker": "BIIB", "Company": "Biogen", "Sector": "Health Care", "Updated": "2022-03-08", "Rating": [{"Date": "2022-03-08", "Rating": "Downgrade", "Organization": "Stifel", "Rating_Change": "Buy to Hold", "Target_Change": "$304 to $223"}, {"Date": "2022-03-03", "Rating": "Upgrade", "Organization": "RBC Capital Mkts", "Rating_Change": "Sector Perform to Outperform", "Target_Change": "$227 to $248"}, {"Date": "2022-02-04", "Rating": "Reiterated", "Organization": "Wolfe Research", "Rating_Change": "Peer Perform", "Target_Change": "$244 to $217"}, {"Date": "2022-02-04", "Rating": "Reiterated", "Organization": "Wells Fargo", "Rating_Change": "Equal Weight", "Target_Change": "$284 to $235"}, {"Date": "2022-02-04", "Rating": "Reiterated", "Organization": "RBC Capital Mkts", "Rating_Change": "Sector Perform", "Target_Change": "$225 to $227"}, {"Date": "2022-02-04", "Rating": "Reiterated", "Organization": "Oppenheimer", "Rating_Change": "Outperform", "Target_Change": "$350 to $285"}, {"Date": "2022-02-04", "Rating": "Reiterated", "Organization": "Needham", "Rating_Change": "Buy", "Target_Change": "$292 to $290"}, {"Date": "2022-02-04", "Rating": "Reiterated", "Organization": "BofA Securities", "Rating_Change": "Neutral", "Target_Change": "$245 to $230"}, {"Date": "2022-02-04", "Rating": "Reiterated", "Organization": "Barclays", "Rating_Change": "Equal Weight", "Target_Change": "$244 to $235"}, {"Date": "2022-02-04", "Rating": "Downgrade", "Organization": "BMO Capital Markets", "Rating_Change": "Outperform to Market Perform", "Target_Change": "$260 to $238"}, {"Date": "2022-02-04", "Rating": "Reiterated", "Organization": "Wedbush", "Rating_Change": "Neutral", "Target_Change": "$195 to $185"}, {"Date": "2022-02-04", "Rating": "Reiterated", "Organization": "Robert W. Baird", "Rating_Change": "Neutral", "Target_Change": "$258 to $224"}, {"Date": "2022-02-04", "Rating": "Reiterated", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$360 to $330"}, {"Date": "2022-02-04", "Rating": "Reiterated", "Organization": "Cowen", "Rating_Change": "Outperform", "Target_Change": "$375 to $285"}, {"Date": "2022-01-13", "Rating": "Downgrade", "Organization": "Guggenheim", "Rating_Change": "Buy to Neutral", "Target_Change": "$290 to $202"}, {"Date": "2022-01-12", "Rating": "Downgrade", "Organization": "Piper Sandler", "Rating_Change": "Overweight to Neutral", "Target_Change": "$362 to $216"}, {"Date": "2021-12-10", "Rating": "Resumed", "Organization": "Raymond James", "Rating_Change": "Mkt Perform", "Target_Change": ""}, {"Date": "2021-12-09", "Rating": "Resumed", "Organization": "Wells Fargo", "Rating_Change": "Equal Weight", "Target_Change": "$250"}, {"Date": "2021-12-06", "Rating": "Initiated", "Organization": "Goldman", "Rating_Change": "Neutral", "Target_Change": "$271"}, {"Date": "2021-11-19", "Rating": "Initiated", "Organization": "BMO Capital Markets", "Rating_Change": "Outperform", "Target_Change": "$315"}, {"Date": "2021-09-23", "Rating": "Initiated", "Organization": "Needham", "Rating_Change": "Buy", "Target_Change": "$400"}, {"Date": "2021-06-18", "Rating": "Upgrade", "Organization": "Piper Sandler", "Rating_Change": "Neutral to Overweight", "Target_Change": "$384 to $450"}, {"Date": "2021-06-14", "Rating": "Reiterated", "Organization": "Truist", "Rating_Change": "Buy", "Target_Change": "$458 to $647"}, {"Date": "2021-06-11", "Rating": "Upgrade", "Organization": "Bernstein", "Rating_Change": "Mkt Perform to Outperform", "Target_Change": "$500"}, {"Date": "2021-06-10", "Rating": "Upgrade", "Organization": "UBS", "Rating_Change": "Neutral to Buy", "Target_Change": ""}, {"Date": "2021-06-08", "Rating": "Upgrade", "Organization": "William Blair", "Rating_Change": "Mkt Perform to Outperform", "Target_Change": ""}, {"Date": "2021-06-08", "Rating": "Upgrade", "Organization": "Robert W. Baird", "Rating_Change": "Underperform to Neutral", "Target_Change": "$216 to $382"}, {"Date": "2021-06-08", "Rating": "Upgrade", "Organization": "Citigroup", "Rating_Change": "Sell to Neutral", "Target_Change": "$200 to $440"}, {"Date": "2021-06-08", "Rating": "Upgrade", "Organization": "Atlantic Equities", "Rating_Change": "Underweight to Neutral", "Target_Change": "$415"}, {"Date": "2021-06-08", "Rating": "Reiterated", "Organization": "Stifel", "Rating_Change": "Buy", "Target_Change": "$346 to $446"}, {"Date": "2021-06-08", "Rating": "Reiterated", "Organization": "RBC Capital Mkts", "Rating_Change": "Sector Perform", "Target_Change": "$259 to $400"}, {"Date": "2021-06-08", "Rating": "Reiterated", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$343 to $455"}, {"Date": "2021-06-08", "Rating": "Reiterated", "Organization": "Jefferies", "Rating_Change": "Buy", "Target_Change": "$450 to $500"}, {"Date": "2021-06-08", "Rating": "Reiterated", "Organization": "H.C. Wainwright", "Rating_Change": "Buy", "Target_Change": "$305 to $452"}, {"Date": "2021-06-08", "Rating": "Reiterated", "Organization": "Barclays", "Rating_Change": "Equal Weight", "Target_Change": "$265 to $395"}, {"Date": "2021-06-07", "Rating": "Upgrade", "Organization": "Raymond James", "Rating_Change": "Underperform to Mkt Perform", "Target_Change": ""}]}